<DOC>
	<DOCNO>NCT02367495</DOCNO>
	<brief_summary>Hypothesis : Angioplasty novel paclitaxel-coated balloon ( PCB ; Agent , Boston Scientific ) citrate-based excipient non-inferior conventional paclitaxel-coated balloon iopromide excipient ( PCB ) treatment coronary restenosis implantation limus-analogue drug-eluting stent ( DES )</brief_summary>
	<brief_title>Trial Novel Paclitaxel-coated Balloon With Citrate Excipient Restenosis -Limus Analogue DES</brief_title>
	<detailed_description>The optimal management patient present drug-eluting stent ( DES ) restenosis remain unclear . Data recent randomize clinical trial suggest angioplasty drug-coated balloon ( DCB ) associate excellent clinical outcome . However , effectiveness DCB device depend critically specific composition matrix coating may important difference clinical performance different DCB device . The prospective , non-randomized , single arm , historical-control ISAR-DESIRE 3A trial design test hypothesis angioplasty novel paclitaxel-coated balloon citrate-based excipient ( Agent PCB , Boston Scientific ) non-inferior conventional paclitaxel-coated balloon iopromide excipient ( SeQuent Please PCB , B. Braun ; data ISAR-DESIRE 3 ) treatment coronary restenosis implantation limus-analogue drug-eluting stent ( DES ) . The key inclusion criterion patient symptom and/or objective sign ischemia , restenosis site previous limus-analogue DES implantation write , informed consent . The primary endpoint in-segment percent diameter stenosis ( % DS ) 6-8 month follow-up angiography . Sample size calculation base non-inferiority analysis : % DS 35 % Both PCB , non-inferiority margin 7 % absolute , 1-sided α-level 0.05 power 80 % result 102 patient per group . To account possible FU loss 125 patient total enrol .</detailed_description>
	<mesh_term>Coronary Restenosis</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Citric Acid</mesh_term>
	<criteria>1 . Patients ischemic symptom evidence myocardial ischemia presence ≥ 50 % restenosis prior implantation LES native coronary vessel . 2 . Written , inform consent patient participation study . 3 . In woman childbearing potential negative pregnancy test mandatory . 1 . Age &lt; 18 year 2 . Cardiogenic shock 3 . Acute STelevation myocardial infarction within 48 hour symptom onset . 4 . Target lesion locate leave main trunk bypass graft . 5 . Target lesion locate small vessel ( vessel size &lt; 2.0 mm ) 6 . Malignancies comorbid condition ( example severe liver , renal pancreatic disease ) life expectancy le 12 month may result protocol noncompliance . 7 . Severe renal insufficiency ( glomerular filtration rate ≤ 30 ml/min ) 8 . Contraindications antiplatelet therapy , paclitaxel 9 . Pregnancy ( present , suspected plan ) positive pregnancy test . 10 . Previous enrollment trial . 11 . Patient 's inability fully comply study protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Coronary Restenosis</keyword>
	<keyword>restenosis</keyword>
	<keyword>paclitaxel-coated balloon</keyword>
	<keyword>drug-eluting stent</keyword>
	<keyword>drug-coated balloon</keyword>
	<keyword>coronary angiography</keyword>
</DOC>